<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>19(6)</volume><submitter>Zhou Y</submitter><funding>anHang Program of the Naval Military Medical University and “Climbing” program of Changhai hospital.</funding><funding>Wu Jieping Medical Foundation</funding><funding>Stroke Prevention Project of the National Health Commission of the People’s Republic of China</funding><pubmed_abstract>Hyperglycemia is associated with decreased recanalization probability and increased risk of hemorrhagic complications for stroke patients treated with intravenous alteplase. However, whether hyperglycemia modifies alteplase treatment effect on clinical outcome in patients with large vessel occlusion stroke undergoing endovascular thrombectomy is uncertain. We conducted this study to determine a possible interaction effect between admission hyperglycemia and intravenous alteplase prior to thrombectomy in patients with large vessel occlusion stroke. In this post-hoc analysis of a randomized trial (DIRECT-MT) comparing intravenous alteplase before endovascular treatment vs. endovascular treatment only, 649 with available baseline glucose measurements were included. The treatment-by-admission </pubmed_abstract><journal>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</journal><pagination>1932-1941</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9723076</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Effect of Admission Hyperglycemia on Safety and Efficacy of Intravenous Alteplase Before Thrombectomy in Ischemic Stroke: Post-hoc Analysis of the DIRECT-MT trial.</pubmed_title><pmcid>PMC9723076</pmcid><pubmed_authors>Su D</pubmed_authors><pubmed_authors>Liu J</pubmed_authors><pubmed_authors>DIRECT-MT investigators</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors><pubmed_authors>Zhou Y</pubmed_authors><pubmed_authors>Ye X</pubmed_authors><pubmed_authors>Goyal M</pubmed_authors><pubmed_authors>Lu H</pubmed_authors><pubmed_authors>Que X</pubmed_authors><pubmed_authors>Li T</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Yang P</pubmed_authors><pubmed_authors>Wei F</pubmed_authors><pubmed_authors>Han H</pubmed_authors><pubmed_authors>Wang Z</pubmed_authors><pubmed_authors>Ospel J</pubmed_authors><pubmed_authors>McDonough R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Effect of Admission Hyperglycemia on Safety and Efficacy of Intravenous Alteplase Before Thrombectomy in Ischemic Stroke: Post-hoc Analysis of the DIRECT-MT trial.</name><description>Hyperglycemia is associated with decreased recanalization probability and increased risk of hemorrhagic complications for stroke patients treated with intravenous alteplase. However, whether hyperglycemia modifies alteplase treatment effect on clinical outcome in patients with large vessel occlusion stroke undergoing endovascular thrombectomy is uncertain. We conducted this study to determine a possible interaction effect between admission hyperglycemia and intravenous alteplase prior to thrombectomy in patients with large vessel occlusion stroke. In this post-hoc analysis of a randomized trial (DIRECT-MT) comparing intravenous alteplase before endovascular treatment vs. endovascular treatment only, 649 with available baseline glucose measurements were included. The treatment-by-admission </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Oct</publication><modification>2026-05-28T15:30:19.494Z</modification><creation>2025-04-05T15:22:20.141Z</creation></dates><accession>S-EPMC9723076</accession><cross_references><pubmed>36151441</pubmed><doi>10.1007/s13311-022-01281-0</doi></cross_references></HashMap>